Lacey brings more than 30 years of experience in medical research to Unity, including a 17-year tenure at Amgen leading research across multiple disease areas.
Lacey concluded his tenure at Amgen as senior vice president and head of discovery research, leading more than 1,200 scientists in a multi-site research organization covering four broad therapeutic areas, including oncology, inflammation, metabolic disorders, and neuroscience.
He played a fundamental role in the discovery of the OPG/RANKL/RANK pathway that resulted in the therapeutics Prolia for osteoporosis, and Xgeva for cancer-related bone diseases.
Following his retirement from Amgen in 2011, Lacey has advised multiple companies and venture capitalists in the biopharmaceutical industry.
He currently serves on the board of directors for Inbiomotion SL, Atreca, and Nurix, Inc.
Lacey received a bachelor's degree in biology and medical doctorate from the University of Colorado and is board certified in anatomical pathology.
Privately held Unity biotechnology is developing therapeutics that increase health span by preventing, halting, or reversing diseases of aging.
The company's initial focus is on creating senolytic medicines to selectively eliminate senescent cells and thereby treat age-related afflictions such as osteoarthritis, atherosclerosis, eye diseases, and kidney disease.
Its management team has collectively moved more than 90 therapeutic candidates into human clinical trials and developed 13 FDA-approved medicines.
AbbVie's ELAHERE receives full US FDA approval
Johnson & Johnson's OPSYNVI receives US FDA approval
Outlook Therapeutics receives positive CHMP opinion for ONS-5010 in wet AMD treatment
Human Immunology Biosciences receives ODD from FDA for felzartamab
Eton Pharmaceuticals acquires PKU GOLIKE, expanding rare disease portfolio
Vertex receives FDA clearance for VX-407 Investigational New Drug Application for ADPKD
Phanes Therapeutics receives FDA Fast Track designation for PT886
Bio-Thera Solutions signs new licensing agreement with SteinCares
FDA accepts resubmission of Citius Pharmaceuticals, Inc's BLA for LYMPHIR
GSK Plc reports positive Phase III Jemperli data for endometrial cancer
ImmVira receives FDA Fast Track designation for MVR-T3011 IT